Pallas Capital Advisors LLC Buys Shares of 15,805 CVS Health Corporation $CVS

Pallas Capital Advisors LLC bought a new stake in shares of CVS Health Corporation (NYSE:CVS) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 15,805 shares of the pharmacy operator’s stock, valued at approximately $1,635,000.

Other hedge funds have also made changes to their positions in the company. Caitong International Asset Management Co. Ltd grew its stake in CVS Health by 407.2% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock worth $26,000 after buying an additional 281 shares during the last quarter. Swiss RE Ltd. bought a new stake in CVS Health in the fourth quarter valued at $26,000. Sankala Group LLC acquired a new position in shares of CVS Health during the fourth quarter valued at $28,000. Global Trust Asset Management LLC grew its position in shares of CVS Health by 344.8% during the first quarter. Global Trust Asset Management LLC now owns 387 shares of the pharmacy operator’s stock worth $28,000 after acquiring an additional 300 shares during the last quarter. Finally, Mcguire Capital Advisors Inc. bought a new position in shares of CVS Health during the fourth quarter worth about $28,000. Institutional investors own 80.66% of the company’s stock.

CVS Health Stock Performance

Shares of CVS opened at $93.99 on Tuesday. The firm has a market capitalization of $120.21 billion, a PE ratio of 24.87, a P/E/G ratio of 0.93 and a beta of 0.61. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.74. The firm has a 50-day moving average price of $102.46 and a 200 day moving average price of $88.41. CVS Health Corporation has a 52-week low of $69.40 and a 52-week high of $110.68.

CVS Health (NYSE:CVS) last issued its quarterly earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 earnings per share for the quarter, topping analysts’ consensus estimates of $1.87 by $0.71. CVS Health had a net margin of 1.18% and a return on equity of 13.12%. The company had revenue of $106.10 billion during the quarter, compared to analyst estimates of $100.03 billion. During the same period in the prior year, the business posted $1.81 EPS. The business’s revenue for the quarter was up 7.3% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. On average, sell-side analysts anticipate that CVS Health Corporation will post 8.02 earnings per share for the current fiscal year.

CVS Health Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, August 3rd. Stockholders of record on Thursday, July 23rd were given a dividend of $0.665 per share. The ex-dividend date was Thursday, July 23rd. This represents a $2.66 annualized dividend and a dividend yield of 2.8%. CVS Health’s dividend payout ratio (DPR) is 70.37%.

Insider Activity at CVS Health

In other news, Director Larry Robbins sold 370,462 shares of the business’s stock in a transaction on Thursday, May 21st. The stock was sold at an average price of $93.45, for a total value of $34,619,673.90. Following the sale, the director owned 4,824,799 shares of the company’s stock, valued at approximately $450,877,466.55. The trade was a 7.13% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.85% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on CVS shares. JPMorgan Chase & Co. lifted their price objective on shares of CVS Health from $111.00 to $118.00 and gave the company an “overweight” rating in a research report on Wednesday, August 12th. Robert W. Baird set a $107.00 price target on shares of CVS Health in a research note on Thursday, August 6th. Morgan Stanley lifted their price target on CVS Health from $106.00 to $111.00 and gave the company an “overweight” rating in a report on Thursday, June 4th. TD Cowen boosted their price objective on CVS Health from $105.00 to $110.00 and gave the stock a “buy” rating in a research report on Monday, May 11th. Finally, Piper Sandler restated an “overweight” rating and issued a $113.00 target price on shares of CVS Health in a research report on Monday, June 1st. Twenty-two analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $106.75.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.